Stock market data from reputable financial news sources or stock exchanges

Roche to Acquire Poseida Therapeutics for $9 Per Share Plus $4 CVR in $1.5 Billion CAR-T Deal

Nov 26, 2024, 06:45 AM

Roche Holding AG has entered into a definitive agreement to acquire California-based Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in CAR-T cell therapies, for $9 per share in cash, totaling $1 billion upfront. Shareholders will also receive a non-tradeable contingent value right (CVR) of up to $4 per share, bringing the total potential value of the deal to $1.5 billion. This transaction represents a significant premium of approximately 200% over Poseida's recent share price. The acquisition includes Poseida's cell therapy candidates and related platform technologies, which focus on developing off-the-shelf CAR-T therapies for the treatment of autoimmune diseases, hematological malignancies, and solid tumors.